Overview

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
Phase:
Phase 3
Details
Lead Sponsor:
RedHill Biopharma Limited